GlassScriptPhysician profile
Roxanne M Johnson
NPI 1609912450
$2,529.87
in general payments reported to CMS, 2019-2025
15 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $296 · 2022: $592 · 2023: $524 · 2024: $654 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $835.03 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $323.18 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $288.32 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $236.74 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $157.58 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $137.49 | 2022-2025 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $103.84 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $100.02 | 2021-2024 | Trintellix |
| Lundbeck LLC | $97.62 | 2021-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $72.75 | 2021-2023 | Belsomra |
| Axsome Therapeutics, INC. | $67.45 | 2022-2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.03 | 2021 | |
| Idorsia Pharmaceuticals US INC | $32.75 | 2023 | Quviviq |
| Eisai INC. | $24.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.96 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.